| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S13513 R52200 |
Fitton - Calcium blockers (Controls unexposed, disease free), 2020 | Small for gestational age (birth weight below the 10th percentile) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, disease free excluded | Adjustment: Yes Indications Antihypertensive: All hypertensions, any indications or not specified |
1.24 [0.64;2.39] excluded (control group) |
18/167 24,121/250,693 | 24,139 | 167 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S14422 R57252 |
Fitton - Calcium blockers (Controls unexposed, sick), 2020 | Small for gestational age (birth weight below the 10th percentile) | during pregnancy (anytime or not specified) | retrospective cohort (claims database) | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 0.79 [0.48;1.29] C | 18/167 1,059/7,971 | 1,077 | 167 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13922 R54506 |
Fisher b - Calcium inhibitors (Controls unexposed, disease free), 2018 | Small for gestational age (birthweight < 10th percentile for a given gestational age in weeks, sex, race/ethnicity, and parity) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified |
1.98 [0.37;7.01] excluded (control group) |
3/18 923/9,219 | 926 | 18 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13923 R54507 |
Fisher b - Calcium inhibitors (Controls unexposed, sick), 2018 | Small for gestational age (birthweight < 10th percentile for a given gestational age in weeks, sex, race/ethnicity, and parity) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 1.46 [0.42;5.14] C | 3/18 101/839 | 104 | 18 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13449 R51812 |
Su - Calcium blockers (Controls unexposed, disease free), 2013 | Small for gestational age (<10th percentile for gestational age and gender) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, disease free excluded | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication |
1.79 [1.37;2.34] C excluded (control group) |
74/303 1,250/8,181 | 1,324 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13443 R51794 |
Su - Calcium blockers (Controls unexposed, sick), 2013 | Small for gestational age (<10th percentile for gestational age and gender) | during pregnancy (anytime or not specified) | population based cohort retrospective | unexposed, sick | Adjustment: Yes Indications Antihypertensive: Only chronic hypertension indication | 1.45 [1.06;1.97] | 74/303 184/1,006 | 258 | 303 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13469 R51950 |
Nakhai-Pour - Calcium blockers, 2010 | Small for gestational age (a birth weight less than the 10th percentile for that gestational age and gender) | 2nd and/or 3rd trimester | nested case control | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified | 2.19 [0.09;53.74] C | 0/1 7,445/56,333 | 7,445 | 1 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13789 R54071 |
Bayliss - Calcium blockers, 2002 | Small for gestational age (birth weight for gestation on or below the 10th percentile using Gairdner– Pearson growth charts) | throughout pregnancy | retrospective cohort | unexposed, sick | Adjustment: No Indications Antihypertensive: Only chronic hypertension indication | 0.68 [0.18;2.54] C | 3/14 49/171 | 52 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S13988 R54962 |
Magee - Calcium blockers, 1996 | Small for gestational age (NOS) | at least 1st trimester | prospective cohort | unexposed (general population or NOS) | Adjustment: No Indications Antihypertensive: All hypertensions, any indications or not specified Matched | 4.49 [0.49;41.36] C | 4/61 1/65 | 5 | 61 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 6 studies | 1.17 [0.81;1.70] | 8,941 | 564 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Controls unexposed, sick;
Asymetry test p-value = 0.9315 (by Egger's regression)
slope=0.1873 (0.2550); intercept=0.0747 (0.8170); t=0.0915; p=0.9315
excluded 13449, 13922, 13513